Edition:
United Kingdom

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

10.50USD
20 Jun 2018
Change (% chg)

$0.50 (+5.00%)
Prev Close
$10.00
Open
$9.80
Day's High
$10.68
Day's Low
$9.70
Volume
297,324
Avg. Vol
21,998
52-wk High
$12.00
52-wk Low
$6.60

Select another date:

Tue, May 8 2018

BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36

* KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

FDA approves Kindred treatment for problem weight loss in cats

Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

UPDATE 1-FDA approves Kindred treatment for problem weight loss in cats

May 7 Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

FDA approves Kindred's weight-loss ointment for cats

May 7 Kindred Biosciences inc said on Monday the U.S. Food and Drug Administration had approved its topical treatment for unintended weight loss in cats.

BRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement

* KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT - SEC FILING

BRIEF-Kindred Biosciences Receives FDA Approval Of Mirataz For The Management Of Weight Loss In Cats

* KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS

BRIEF-Kindred Biosciences Announces Board Appointments

* KINDRED BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DR. ERNEST MARIO AND DR. JOSEPH MCCRACKEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Kindred Biosciences Q4 Loss Per Share $0.35

* KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Kindred Biosciences Inc Files For Mixed Shelf Of Up To $150 Million

* KINDRED BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING‍​ Source text - (http://bit.ly/2risHPv) Further company coverage:

BRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz

* KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™

Select another date: